Quanterix Corp

Quanterix Corporation develops and commercializes digital immunoassay platforms designed for protein detection and measurement in life sciences research and clinical diagnostics. The company's core technology, Simoa (Single Molecule Array), enables ultrasensitive detection of biomarkers across multiple therapeutic areas including neurology, oncology, immunology, and inflammation. Its product portfolio comprises the HD-X and SR-X instruments, which serve as protein detection platforms, and the SP-X instrument, which utilizes planar array technology for multiplex chemiluminescent immunoassays. The company also manufactures consumable assays containing beads, reagents, and antibodies required to operate these instruments.

Revenue is generated through multiple streams: instrument sales, consumable assays and replacement parts, and contract research services. Contract services include sample testing, custom assay development, and diagnostic testing services. The company serves the life sciences research sector primarily through direct sales to academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. It also operates through distributors and sales agents.

Quanterix has 471 full-time employees and is headquartered in Billerica, Massachusetts. The company maintains geographic reach across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. Quanterix was incorporated in Delaware in 2007 and is listed on Nasdaq.